We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma. Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, Triple-action Rhopressa™ and Quadruple-action Roclatan™, are once-daily eye drops that, if approved, will provide eye-care professionals with the first novel intraocular pressure-lowering mechanisms of action, or MOA, to treat glaucoma in nearly 20 years.
Jul 22, 2015
Aerie Pharmaceuticals to Announce Second Quarter 2015 Financial Results and Host Conference Call on Wednesday, August 5, 2015
Jul 1, 2015
Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2015 Healthcare Conference
View all »Events & Presentations
Aug 5, 2015 at 5:00 PM ET
Aerie Pharmaceuticals, Inc. Second Quarter 2015 Earnings Call